All the patients enrolled in the present study had recurrent disease after definitive local treatment or advanced NSCLC, and some patients had already been treated with some type of systemic therapy; therefore, the relationship between the primary tumor size or the clinical stage and the sPD‐L1 level could not be evaluated. This evidence concerns the gene SPDL1 and neoplasm.